Mergers & Acquisitions - Shire, Mergers & Acquisitions

Filter

Popular Filters

Analysts view Shire defense as independent pharma

Analysts view Shire defense as independent pharma

24-06-2014

There has been quite a lot of reaction to yesterday’s presentation by Ireland-headquartered Shire's…

AbbVieMergers & AcquisitionsPharmaceuticalShire

Shire sets out robust defense for rejecting AbbVie takeover bid

Shire sets out robust defense for rejecting AbbVie takeover bid

23-06-2014

Ireland-headquartered Shire today presented a robust defense of its position as an independent pharmaceutical…

AbbVieMergers & AcquisitionsPharmaceuticalShire

Shire rejects unsolicited $46.5 billion takeover offer from AbbVie

Shire rejects unsolicited $46.5 billion takeover offer from AbbVie

20-06-2014

Ireland headquartered Shire has this morning revealed that it has received, and rejected, an unsolicited…

AbbVieMergers & AcquisitionsPharmaceuticalShire

Shire acquires Lumena Pharma, adding to rare disease portfolio

Shire acquires Lumena Pharma, adding to rare disease portfolio

12-05-2014

Ireland-headquartered drugmaker Shire says it will acquire San Diego, USA-based rare disease focussed…

Lumena PharmaceuticalsMergers & AcquisitionsPharmaceuticalRare diseasesShire

Report: Life science companies experience IPO slowdown

10-12-2013

Life sciences companies have been completing fewer initial public offerings (IPOs) this season as the…

Mergers & AcquisitionsPharmaceuticalRocheSalix PharmaceuticalsShireUSA

Shire’s acquisition of ViroPharma will add $831m in revenue by 2018, says GlobalData

Shire’s acquisition of ViroPharma will add $831m in revenue by 2018, says GlobalData

19-11-2013

Ireland-based drugmaker Shire’s (LSE: SHP) buy-out of US orphan drug company ViroPharma (Nasdaq: VPHM)…

CinryzeEuropeFinancialMergers & AcquisitionsPharmaceuticalShireUSAViroPharma

Shire strengthens position in rare diseases with $4.2 billion buy of ViroPharma

Shire strengthens position in rare diseases with $4.2 billion buy of ViroPharma

11-11-2013

Ireland-based drugmaker Shire saw its share rise 2.2% to £33.16 shortly after markets opened this morning,…

CinryzeFirazyrMergers & AcquisitionsPharmaceuticalRare diseasesShireViroPharma

Shire to buy SARcode Bioscience for $160 million plus milestones

26-03-2013

In a third takeover announcement this year, Ireland-headquartered Shire (LSE: SHP) says it plans to acquire…

LifitegrastMergers & AcquisitionsOphthalmicsPharmaceuticalSARcode BiosciencesShire

Shire acquires Premacure to expand in new therapy area

13-03-2013

In a second acquisition so far this year, Ireland-headquartered drugmaker Shire (LSE: SHP) said on Tuesday…

BiotechnologyMergers & AcquisitionsOphthalmicsPharmaceuticalPremacureRare diseasesShire

AstraZeneca management shakeup sign of major restructuring leading to stock recovery, say analysts

17-01-2013

The management changes at Anglo-Swedish drug major AstraZeneca (LSE: AZN) announced this week do not…

AstraZenecaBrilintaBriliqueFinancialManagementMergers & AcquisitionsPharmaceuticalShire

Shire to acquire Lotus Tissue Repair for undisclosed price

09-01-2013

Ireland-headquartered drugmaker Shire (LSE: SHP) said yesterday that it has signed an agreement to acquire…

BiotechnologyLotus Tissue RepairMergers & AcquisitionsPharmaceuticalRare diseasesShire

Shire inks deal to buy Pervasis, adding Ph II drug candidate

13-04-2012

Ireland-headquartered biopharma firm Shire (LSE: SHP) said yesterday that it has signed an agreement…

Mergers & AcquisitionsPervasis TherapeuticsPharmaceuticalShire

Shire to acquire FerroKin BioSciences; drops Replagal BLA

16-03-2012

Ireland-headquartered Shire (LSE: SHP) said yesterday that it has signed an agreement to acquire privately-held…

FerroKin BioSciencesMergers & AcquisitionsNorth AmericaOncologyPharmaceuticalRare diseasesRegulationReplagalShire

Shire gets US Rights to Resolor

10-01-2012

Ireland-headquartered specialty biopharma firm Shire (LSE: SHP) says that it has acquired the rights…

Gastro-intestinalsMarkets & MarketingMergers & AcquisitionsNorth AmericaPharmaceuticalResolorShire

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top